default author photo

Raanan Berger

Chaim Sheba Medical Center

Tel-Hashomer

Israel

SCHOLARLY PAPERS

1

DOWNLOADS

60

TOTAL CITATIONS

0

Scholarly Papers (1)

1.

Transcriptomics in Tumor and Normal Tissues and Precision Oncology Algorithms Identify Early-Stage NSCLC Patients with High Risk of Post-Surgery Recurrence Who May Benefit from Adjuvant Therapies

Number of pages: 28 Posted: 24 Aug 2021
WIN Consortium - Worldwide Innovative Network (WIN) Association, Groupe Hospitalier Saint-Joseph, École Normale Supérieure - PSL Research University - Institut Curie, Pfizer, Inc., AstraZeneca Pharmaceuticals, WIN Consortium - Worldwide Innovative Network (WIN) Association, WIN Consortium - Worldwide Innovative Network (WIN) Association, Avera Cancer Institute, WIN Consortium - Worldwide Innovative Network (WIN) Association, Hebrew University of Jerusalem - The Sharett Institute of Oncology, Chaim Sheba Medical Center, Chaim Sheba Medical Center, Fudan University - Department of Thoracic SurgeryFudan University - Shanghai Cancer Center, King Hussein Cancer Center (KHCC), Tokyo Medical and Dental University, University of Copenhagen - Rigshospitalet, I.M. Sechenov First Moscow State Medical University, Hospital Vall d’Hebron, Vall d’Hebron Institute of Oncology (VHIO)Hospital Vall d’Hebron, McGill University - Segal Cancer Center, McGill University - Segal Cancer Center, Tata Memorial Centre - Tata Memorial Hospital, Institut Mutualiste Montsouris, University of Claude Bernard Lyon 1 - Medical Oncology Department, École Normale Supérieure - PSL Research University - Institut Curie, Iuliu Hatieganu University of Medicine and Pharmacy, Ben-Gurion University of the NegevIuliu Hatieganu University of Medicine and Pharmacy, Ben-Gurion University of the NegevIuliu Hatieganu University of Medicine and Pharmacy, WIN Consortium - Worldwide Innovative Network (WIN) Association and WIN Consortium - Worldwide Innovative Network (WIN) Association
Downloads 60 (961,006)

Abstract:

Loading...

NSCLC, outcome , trascriptomics, DDPP, adjuvant therapies, precision medicine, WIN Consortium